Read + Share
Saltos AN, Creelan BC, Tanvetyanon T, Chiappori AA, et al. A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC
harboring activating KRAS or EGFR mutations. Lung Cancer 2023;183:107313.
PMID: 37499521
|
 |
|
Saltos AN, Creelan BC, Tanvetyanon T, Chiappori AA, et al. A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC
harboring activating KRAS or EGFR mutations. Lung Cancer 2023;183:107313.
PMID: 37499521
|
|
|
|